Trial · NCT07882784
Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage
NCT07882784, Not yet recruiting, University Medical Centre Maribor
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage. Trials, record NCT07882784. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07882784
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Outcome Prediction and Recovery After Spontaneous Intracerebral Haemorrhage
- NCT number
- NCT07882784
- Status
- Not yet recruiting
- Enrollment
- 300 participants, estimated
- Lead sponsor
- University Medical Centre Maribor
- Conditions
- Intracerebral Hemorrhage, Hemorrhagic Stroke
- First posted
- 2026-10-20
- Last updated
- 2026-10-20
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Unfavourable functional outcome at 12 months (modified Rankin Scale 4-6) | 12 months after ICH onset | Proportion of participants with mRS 4-6 (unfavourable) versus 0-3. The mRS ranges from 0 (no symptoms) to 6 (death); higher scores indicate worse outcome. Used as the outcome of the multivariable prognostic model. |
| Secondary | Functional outcome on the full ordinal modified Rankin Scale at 12 months | 12 months after ICH onset | Distribution of mRS scores (0 = no symptoms to 6 = death; higher scores indicate worse outcome), analysed with proportional odds regression. |
| Secondary | Functional outcome at 6 months (modified Rankin Scale) | 6 months after ICH onset | mRS score (0 = no symptoms to 6 = death; higher scores indicate worse outcome). |
| Secondary | All-cause mortality | 30 days, 6 months and 12 months after ICH onset | Proportion of participants who died from any cause. |
| Secondary | Change in neurological deficit (NIHSS) during hospitalisation | Admission, approximately 48 hours, and hospital discharge (up to approximately 4 weeks) | National Institutes of Health Stroke Scale score (0-42; higher scores indicate more severe deficit). |
| Secondary | Neurological deficit at follow-up (NIHSS) | 6 and 12 months after ICH onset | National Institutes of Health Stroke Scale score (0-42; higher scores indicate more severe deficit). |
| Secondary | Pain burden during hospitalisation | From admission to hospital discharge (up to approximately 4 weeks) | Pain assessed hierarchically according to communication ability: Numeric Rating Scale 0-10 (higher = more pain) in communicative patients; Behavioural Pain Scale, revised Nociception Coma Scale, PAIC15 or Doloplus-2 in non-communicative patients. |
| Secondary | Pain intensity at follow-up (Numeric Rating Scale) | 6 and 12 months after ICH onset | Numeric Rating Scale 0-10 (0 = no pain, 10 = worst imaginable pain). |
| Secondary | Health-related quality of life (PROMIS-29) | 6 and 12 months after ICH onset | PROMIS-29 domain T-scores (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles, pain interference) and pain intensity item. Higher scores indicate more of the domain measured. |
| Secondary | Self-rated health (EQ-5D VAS) | 6 and 12 months after ICH onset | EuroQol visual analogue scale, 0 (worst imaginable health) to 100 (best imaginable health). |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07882784
GET https://conductscience.org/api/trials/v1/NCT07882784/registered